Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table S1 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors
  1. Home
  2. Publications
  3. Supplementary Table S1 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors

Supplementary Table S1 from Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors

Authors:
  • HXHuaiyuan Xu
    Huaiyuan Xu
  • JHJinxin Hu
    Jinxin Hu
  • YZYun Zhang
    Yun Zhang
  • AZAihua Zhuang
    Aihua Zhuang
  • YZYingchun Zhang
    Yingchun Zhang
  • JLJibin Li
    Jibin Li
  • HWHao Wu
    Hao Wu
  • GSGuohui Song
    Guohui Song
  • CDChuanquan Deng
    Chuanquan Deng
  • HCHongmin Chen
    Hongmin Chen
  • WCWeiqing Chen
    Weiqing Chen
  • CDChuangzhong Deng
    Chuangzhong Deng

Open Access
Publisher website
Google Scholar
  • 1 June 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.32530919
Abstract
Table S1. Representativeness of study participants
Keywords
  • CHEMOTHERAPY
  • CLINICAL TRIAL RESULTS
  • PHASE III CLINICAL TRIALS
  • SARCOMAS
  • SOFT-TISSUE SARCOMA
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.